Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Multiple A-share listed companies deliver strong earnings as the year begins; semiconductor and pharmaceutical track high prosperity stands out
According to Wind data, as of March 23, a total of 8 A-share listed companies have disclosed their first-quarter earnings forecasts. Among them, one company remains in continued loss, while the others are expected to see increases, slight increases, or turnarounds. At the same time, many A-share companies have also densely disclosed operational data for the first two months, voluntarily sharing their early-year performance reports ahead of schedule. After review, most of the companies with growth in performance are concentrated in high-growth sectors such as pharmaceuticals and semiconductors.
Jian Junhao, founder of Fujian Huace Brand Positioning Consulting, told Securities Daily that since the beginning of the year, many A-share companies have disclosed operational data, showing a strong overall start. “The profitability realization of these companies is high, indicating that industry recovery is not just hype but driven by genuine demand and capacity release, laying a solid foundation for full-year performance.”
Taking semiconductors as an example, Haiguang Information Technology Co., Ltd. (hereinafter “Haiguang Information”) mainly engages in the research and development of high-end processors, accelerators, and other computing chip products and systems. The company expects its revenue in the first quarter of 2026 to increase by 62.91% to 75.82% year-on-year; net profit attributable to the parent company is projected to be between 620 million yuan and 720 million yuan, up 22.56% to 42.32% year-on-year.
Haiguang Information stated that the company continues to increase R&D investment, strengthening product competitiveness. Domestic high-end chips are seeing rising market demand driven by the AI industry’s growth. Through sustained R&D investment, ongoing product performance optimization, and faster product iteration, the company is expanding its market share in high-end processors, resulting in significant revenue growth and continuous overall performance improvement.
Operational data from related listed companies in the first two months also reflect the high prosperity of the semiconductor industry. On March 4, Shenzhen Buwei Storage Technology Co., Ltd. (hereinafter “Buwei Storage”) announced that, based on preliminary estimates, revenue from January to February 2026 is expected to reach 4 billion to 4.5 billion yuan, a year-on-year increase of 340% to 395%; net profit attributable to the parent company is projected to be between 1.5 billion and 1.8 billion yuan, up 921.77% to 1086.13%.
Buwei Storage said that 2026 marks a high prosperity cycle for the storage industry. Driven by AI computing power and domestic substitution, the prices of DRAM (dynamic random-access memory) continue to rise, with supply and demand in the industry remaining tight, benefiting the company significantly. Meanwhile, to enhance its market competitiveness in the AI era, the company continues to increase investments in chip design, solutions, advanced packaging, testing, and equipment.
Shanghai Weice Semiconductor Technology Co., Ltd. mainly provides integrated circuit testing services. The announcement shows that from January to February, the company achieved a consolidated revenue of 321 million yuan, a year-on-year increase of 79.15%. The significant improvement in operating performance during this period is mainly due to the new capacity being put into use, a notable increase in high-end testing sales, and rising capacity utilization.
Qiangyi Semiconductor (Suzhou) Co., Ltd. also announced that, based on preliminary calculations by the finance department, its consolidated revenue from January to February 2026 reached 164 million yuan, a year-on-year increase of 157.90%. The remarkable performance growth during this period is mainly driven by the explosive demand for AI computing power and the prosperity cycle of the semiconductor industry, with strong demand from leading downstream clients, and rapid growth in high-end MEMS probe card business.
Jian Junhao further believes that the core driver behind the performance of these semiconductor-related companies is the surge in AI computing power demand, which has led to rising prices and volumes of upstream chips, coupled with the end of industry destocking and improved supply-demand patterns. Meanwhile, domestic substitution is accelerating, with local companies continuously increasing orders and market share, jointly driving rapid performance growth through volume and price increases.
In the pharmaceutical sector, benefiting from the implementation of medical insurance policies and commercialization, innovative drug companies are experiencing steady growth. On March 7, Wanjiaode Pharmaceutical Holdings Group Co., Ltd. (hereinafter “Wanjiaode”) released its first-quarter 2026 performance forecast. The company expects to achieve a net profit attributable to the parent of 165 million yuan, a year-on-year increase of 985.4%.
Regarding the significant increase in performance, Wanjiaode stated that the company’s strategic shift from generic drugs to innovative drugs has begun to show results during the reporting period, with positive progress in business expansion, creating new growth points. Additionally, the company has strengthened internal management, increased efforts to recover receivables, and effectively accelerated capital turnover.
Shanghai Ailis Pharmaceutical Technology Co., Ltd. (hereinafter “Ailis”) is an innovative drug company focused on tumor treatment. The company expects its revenue in the first quarter of 2026 to reach 1.55 billion yuan, a year-on-year increase of 41.12%; net profit is projected at 590 million yuan, up 43.73%.
Ailis stated that supported by national medical insurance policies and coverage, sales revenue from commercialized products and promotional services continues to grow, driving the company’s operating performance to keep climbing.
Giant Fubon Investment’s senior investment advisor Ding Zhenyu told reporters, “The strong start of these listed companies fully validates the logical basis of AI computing power and domestic substitution. Overall, their performance growth is mainly driven by core business expansion and volume-price increases, rather than one-time gains. This sustainability results from industry cycle upswings and technological iteration resonating together.”